IDEAYA Biosciences (IDYA) EBITDA (2018 - 2026)

IDEAYA Biosciences has reported EBITDA for 9 years, with the latest figure at -$108.5 million in Q1 2026.

• Quarterly EBITDA fell 28.62% year-over-year to -$108.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$183.5 million (up 49.09% YoY) and the FY2025 annual result came in at -$159.3 million, up 51.28% from the prior year.
• EBITDA retreated to -$108.5 million in Q1 2026 per IDYA's latest filing, from -$94.6 million in the prior quarter.
• Over five years, EBITDA peaked at $108.5 million in Q3 2025 and troughed at -$144.1 million in Q4 2024.
• A 5-year average of -$46.6 million and a median of -$41.9 million in 2023 frame the typical range for EBITDA.
• The sharpest annual moves came in 2023 and 2025: EBITDA slumped 5179.7% in 2023, then jumped 262.13% in 2025.
• Over 5 years, EBITDA stood at -$26.4 million in 2022, then tumbled by 58.52% to -$41.9 million in 2023, then slumped by 243.87% to -$144.1 million in 2024, then surged by 34.39% to -$94.6 million in 2025, then decreased by 14.78% to -$108.5 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$108.5 million, -$94.6 million, and $108.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.